Cargando…

When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest

BACKGROUND: Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years. While financial conflicts of interest (FCOI) between PAOs and industry have received more attention in recent years, robust efforts to mit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehrlich, Orna, Wingate, Laura, Heller, Caren, de Melo-Martin, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918599/
https://www.ncbi.nlm.nih.gov/pubmed/31847854
http://dx.doi.org/10.1186/s12910-019-0435-1
_version_ 1783480622954577920
author Ehrlich, Orna
Wingate, Laura
Heller, Caren
de Melo-Martin, Inmaculada
author_facet Ehrlich, Orna
Wingate, Laura
Heller, Caren
de Melo-Martin, Inmaculada
author_sort Ehrlich, Orna
collection PubMed
description BACKGROUND: Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years. While financial conflicts of interest (FCOI) between PAOs and industry have received more attention in recent years, robust efforts to mitigate these conflicts are still limited. MAIN BODY: The authors outline the possible benefits and ethical concerns that can result from financial interactions between biomedical companies and PAOs. They argue that the use of novel strategies, such as the creation of a standing ethics committee, could be helpful in managing FCOIs and ensuring the warranted trust of PAO’s constituents. Although ethics committees to address FCOIs are common in the academic context, its use by PAOs is still limited. The authors conclude by describing the process of development and implementation of such an ethics committee at the Crohn’s & Colitis Foundation. CONCLUSIONS: While collaborations with industry can result in conflicts of interest, PAOs can develop strategies to address those conflicts. One such strategy is the creation of a standing independent ethics committee to guide PAOs on new and/or existing programs and protocols as they pertain to their industry relationships.
format Online
Article
Text
id pubmed-6918599
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69185992019-12-20 When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest Ehrlich, Orna Wingate, Laura Heller, Caren de Melo-Martin, Inmaculada BMC Med Ethics Debate BACKGROUND: Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years. While financial conflicts of interest (FCOI) between PAOs and industry have received more attention in recent years, robust efforts to mitigate these conflicts are still limited. MAIN BODY: The authors outline the possible benefits and ethical concerns that can result from financial interactions between biomedical companies and PAOs. They argue that the use of novel strategies, such as the creation of a standing ethics committee, could be helpful in managing FCOIs and ensuring the warranted trust of PAO’s constituents. Although ethics committees to address FCOIs are common in the academic context, its use by PAOs is still limited. The authors conclude by describing the process of development and implementation of such an ethics committee at the Crohn’s & Colitis Foundation. CONCLUSIONS: While collaborations with industry can result in conflicts of interest, PAOs can develop strategies to address those conflicts. One such strategy is the creation of a standing independent ethics committee to guide PAOs on new and/or existing programs and protocols as they pertain to their industry relationships. BioMed Central 2019-12-17 /pmc/articles/PMC6918599/ /pubmed/31847854 http://dx.doi.org/10.1186/s12910-019-0435-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Debate
Ehrlich, Orna
Wingate, Laura
Heller, Caren
de Melo-Martin, Inmaculada
When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
title When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
title_full When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
title_fullStr When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
title_full_unstemmed When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
title_short When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
title_sort when patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918599/
https://www.ncbi.nlm.nih.gov/pubmed/31847854
http://dx.doi.org/10.1186/s12910-019-0435-1
work_keys_str_mv AT ehrlichorna whenpatientadvocacyorganizationsmeetindustryanovelapproachtodealingwithfinancialconflictsofinterest
AT wingatelaura whenpatientadvocacyorganizationsmeetindustryanovelapproachtodealingwithfinancialconflictsofinterest
AT hellercaren whenpatientadvocacyorganizationsmeetindustryanovelapproachtodealingwithfinancialconflictsofinterest
AT demelomartininmaculada whenpatientadvocacyorganizationsmeetindustryanovelapproachtodealingwithfinancialconflictsofinterest